NeuroPace Plunges 26.47% on Mixed Study Results

On May 27, 2025, NeuroPace's stock experienced a significant drop of 26.47% in pre-market trading, reflecting investor reactions to the company's recent clinical study results.

NeuroPace recently announced preliminary one-year results from its NAUTILUS study, which evaluated the RNS® System for treating drug-resistant idiopathic generalized epilepsy (IGE). The study successfully met its primary 12-week safety endpoint, demonstrating a low rate of serious adverse events. However, the primary effectiveness endpoint did not reach statistical significance in the overall population. Despite this, a significant response was observed in a majority subgroup of patients with lower baseline seizure frequency, indicating potential therapeutic benefits for a substantial patient subset.

The study involved 87 implanted patients across 23 US epilepsy centers and showed promising median seizure reduction rates. Patients completing over 12 months of treatment exhibited continued clinical improvement. NeuroPace plans to discuss potential regulatory pathways with the FDA, including pursuing a targeted indication for patients with lower baseline seizure frequency. The company's reaffirmation of its full-year 2025 financial guidance signals confidence in its business performance despite the mixed study results.